摘要目的:从驱动蛋白18B(KIF18B)中寻找具有抗肿瘤免疫效应的细胞毒性T淋巴细胞表位。方法:通过癌症基因图谱数据库和免疫组织化学确认KIF18B的表达。利用免疫表位数据库、超基序法、分子操作环境鉴定表位。酶联免疫斑点法、流式细胞术、钙黄绿素释放试验、人源性肿瘤动物模型用于评价表位体内外抗肿瘤免疫活性。秩和检验分析非正态分布变量的组间差异，独立样本 t检验比较多次检测结果的组间差异。 结果:确证KIF18B为乳腺癌抗原，并筛选获得组织相容性抗原A2.1限制性KIF18B表位——KIF18B-P1。KIF18B-P1组CD8 + T细胞比例、干扰素-γ分泌水平、靶细胞杀伤率均显著高于阴性肽组[(23.98±1.07)%比(8.81±0.34)%， t＝-23.446， P<0.01]，其移植瘤体积明显小于阴性肽组[(0.54±0.11) cm 3比(0.71±0.09) cm 3， t＝5.279， P<0.01]，差异有统计学意义。 结论:KIF18B优势表位KIF18B-P1具有体内外抗肿瘤免疫效应。

abstractsObjective:To isolate the kinesin family member 18B (KIF18B)-derived epitope, which could induce antitumor immunity.Methods:KIF18B expression was confirmed by the cancer genome atla database and immunohistochemistry. Immune epitope database, SYFPEITHIP, and Molecular Operating Environment software were used for epitope identification. Enzyme-linked immunospot, flow cytometry, calcein release assay, and a xenograft mouse model were used to examine the immune antitumour activity. Rank-sum test was used to analyze the differences between groups with non-normally distributed variables. Independent-samples t test was used to compare the continuous variable among the different groups. Results:The human leukocyte antigen-A2.1-restricted KIF18B-derived epitope KIF18B-P1 was identified. Proportion of CD8 + T cells, interferon γ secretion level of CTLs, and killing rate against target cells [(23.98±1.07)% vs. (8.81±0.34)%, t=-23.446, P<0.01] were significantly increased in KIF18B-P1 group as compared with those in negative peptide (NP) group. Similarly, xenograft tumor growth was significantly inhibited in KIF18B-P1 group compared to NP group [(0.54±0.11) cm 3 vs. (0.71±0.09) cm 3,t=5.279, P<0.01]. Conclusion:KIF18B-derived CTL epitope KIF18B-P1 could induce anti-tumor immune effects in vitro and in vivo, which might assist clinicians in the development of therapeutic tumor vaccines.